EVOLVA BIOTECH A/S

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Estimate generation in progress, please wait...
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Bankruptcy Risk 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  1.6% 2.9% 4.5% 18.8% 18.3%  
Credit score (0-100)  76 60 48 8 8  
Credit rating  BBB BB BB B B  
Credit limit (kDKK)  26.4 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12

Net sales  59,908 0 0 0 0  
Gross profit  41,876 49,857 2,917 639 -116  
EBITDA  5,890 5,991 110 -200 -116  
EBIT  182 187 110 -200 -116  
Pre-tax profit (PTP)  -619.5 -724.5 241.4 -187.0 -196.8  
Net earnings  -619.5 -724.5 241.4 -187.0 -196.8  
Pre-tax profit without non-rec. items  -620 -725 241 -187 -197  

 
See the entire income statement

Balance sheet (kDKK) 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12

Tangible assets total  18,191 3,739 0.0 0.0 0.0  
Shareholders equity total  7,246 6,521 6,762 6,575 6,379  
Interest-bearing liabilities  11,674 838 1.1 0.0 0.0  
Balance sheet total (assets)  31,564 21,049 8,057 6,578 6,486  

Net Debt  5,974 -2,816 -96.5 -1,190 -100  
 
See the entire balance sheet

Volume 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12

Net sales  59,908 0 0 0 0  
Net sales growth  0.0% -100.0% 0.0% 0.0% 0.0%  
Gross profit  41,876 49,857 2,917 639 -116  
Gross profit growth  0.0% 19.1% -94.1% -78.1% 0.0%  
Employees  56 0 1 1 0  
Employee growth %  0.0% -100.0% 0.0% 0.0% -100.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  31,564 21,049 8,057 6,578 6,486  
Balance sheet change%  0.0% -33.3% -61.7% -18.4% -1.4%  
Added value  5,889.7 5,991.2 109.9 -199.7 -116.4  
Added value %  9.8% 0.0% 0.0% 0.0% 0.0%  
Investments  12,483 -20,255 -3,739 0 0  

Net sales trend  0.0 -1.0 0.0 0.0 0.0  
EBIT trend  1.0 2.0 3.0 -1.0 -2.0  

Profitability 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
EBITDA %  9.8% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.3% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.4% 0.4% 3.8% -31.3% 100.2%  
Net Earnings %  -1.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  8.5% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  -1.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  1.3% 1.3% 2.0% -1.7% -1.2%  
ROI %  1.7% 2.2% 4.1% -1.9% -1.2%  
ROE %  -8.6% -10.5% 3.6% -2.8% -3.0%  

Solidity 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
Equity ratio %  23.0% 31.0% 83.9% 100.0% 98.3%  
Relative indebtedness %  40.6% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  31.1% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  101.4% -47.0% -87.8% 595.9% 86.0%  
Gearing %  161.1% 12.9% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  17.5% 17.2% 11.0% 11,067.6% 0.0%  

Liquidity 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
Quick Ratio  0.8 1.2 6.2 2,890.0 60.5  
Current Ratio  0.8 1.2 6.2 2,890.0 60.5  
Cash and cash equivalent  5,700.5 3,653.9 97.6 1,189.9 100.2  

Capital use efficiency 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  34.2 0.0 0.0 0.0 0.0  
Current assets / Net sales %  12.2% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -1,913.1 2,781.7 6,756.4 6,575.4 6,378.6  
Net working capital %  -3.2% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
Net sales / employee  1,070 0 0 0 0  
Added value / employee  105 0 110 -200 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  105 0 110 -200 0  
EBIT / employee  3 0 110 -200 0  
Net earnings / employee  -11 0 241 -187 0